Safety/Tolerability Study of AV-412 in Subjects With Refractory or Relapsed Solid Tumor Malignancies

Stopped early · Phase 1

Conditions studied: Tumor

In brief

AV-412 is a new oral therapy developed to inhibit the growth of solid tumors in patients who have not responded to standard therapy or surgical interventions, or who have experienced relapse. This study will test the safety of AV-412 and determine the maximum tolerated dose for the treatment of solid tumors.

Key facts

Study ID

NCT00381654

Run by

AVEO Pharmaceuticals, Inc.

People needed

27

Starts

2006-10-01

Expected to finish

2010-02-01

Last updated by the study team

2011-10-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Johns Hopkins University School of Medicine — Baltimore, Maryland, United States
• Hospital Universitatrio Austral — Buenos Aires, Argentina
• Instituto Médico Especializado Alexander Fleming — Buenos Aires, Argentina

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.